Matinas BioPharma Announces Complete Clinical Response In Three Patients With Serious Invasive Fusarium Infection Following Treatment With MAT2203
Matinas BioPharma Announces Complete Clinical Response In Three Patients With Serious Invasive Fusarium Infection Following Treatment With MAT2203
Matinas BioPharma 宣佈三名嚴重侵襲性鐮刀菌感染患者在接受 MAT2203 治療後獲得完全臨床緩解
Matinas BioPharma 宣佈三名嚴重侵襲性鐮刀菌感染患者在接受 MAT2203 治療後獲得完全臨床緩解
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。